ADC · 림프종

33개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved33 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Induction without Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 2Status Recruiting
ADCLimited DatastaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+1
Trials 2Status Active
ADCLimited DatastaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin Plus CHP)

CD30-Positive Peripheral T-Cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30-PositivePeripheralT-CellLym+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 1

brentuximab vedotin (Adcetris, Brentuximab vedotin and rifampicin)

Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase1#antibody-drug-conjugate#AnaplasticLarge-cellLymphoma+1
Trials 1Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
ADCLimited DatastalePfizerPhase 3

INO (Inotuzumab ozogamicin, Inotuzumab ozogamicin (INO))

B-Cell Acute Lymphoblastic Leukaemia · B-Cell Acute Lymphoblastic Leukaemia

#B-CellAcuteLymphoblasticLeukaemi#ADC#Phase3#antibody-drug-conjugate#Pfizer
Trials 1Status Recruiting
ADCLimited DatastaleMethylGene Inc.Phase 2

brentuximab vedotin (Adcetris, Mocetinostat Plus Brentuximab Vedotin)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#antibody-drug-conjugate#MethylGene
Trials 1Status Active
ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleTG Therapeutics, Inc.Phase 1

brentuximab vedotin (Adcetris, TGR-1202 + brentuximab vedotin)

Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Phase1#antibody-drug-conjugate#TG
Trials 1Status Active

2 / 2 pages

← PreviousNext →